Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Canadian approval for Cipralex

Dec. 30, 2004

Good efficacy and safety profile reported for tiagabine in GAD

Dec. 29, 2004

Phase III data on the efficacy of dexanabinol in severe traumatic brain injury

Dec. 29, 2004

Scientists at Takeda prepare and test RFRP receptor antagonists

Dec. 29, 2004

Not approvable letter for Cellegesic

Dec. 29, 2004

First clinical data for novel antidepressant published

Dec. 28, 2004

TaiGen Biotechnology patent discloses CXCR3 receptor antagonists

Dec. 28, 2004

New treatment for Parkinson's disease described in patent literature

Dec. 28, 2004

Bristol-Myers Squibb and Somerset sign agreement for Emsam

Dec. 28, 2004

Actelion begins global phase IIb/III program for clazosentan

Dec. 28, 2004

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...